Agilus Diagnostics, in partnership with global diagnostics company Sebia, has introduced the Anti-MCV (anti–mutated citrullinated vimentin) antibody test in India—a significant advancement in the early detection of rheumatoid arthritis (RA). Developed by Sebia, this test is particularly beneficial for patients who test negative for conventional RA markers such as anti-CCP (cyclic citrullinated peptide) and rheumatoid factor (RF).
Rheumatoid arthritis, a chronic autoimmune disease, affects an estimated 0.5–1% of India’s population—a number expected to rise with growing awareness and improved diagnostic reach. The launch of the Anti-MCV test by Agilus Diagnostics makes this advanced diagnostic tool more accessible to clinicians and patients across the country.
Unlike traditional markers, the Anti-MCV test identifies antibodies against a mutated form of the vimentin protein, a key biomarker found in the synovial fluid of RA patients. Research indicates that Anti-MCV antibodies can be present in patients with RA symptoms even when anti-CCP and RF tests return negative results. Importantly, these antibodies may be detectable up to two years before the clinical onset of RA, especially in individuals with a strong family history of the condition—enabling earlier diagnosis and intervention.
“Anti-MCV addresses an important diagnostic gap. Studies suggest that 10–15% of RA cases missed by anti-CCP can be identified through Anti-MCV testing,” said Dr. Deepak Sanghavi, Senior Vice President – Operations and Chief of the Mumbai Reference Lab at Agilus Diagnostics. “For patients with persistent joint symptoms but negative CCP and RF results, this test offers clinicians a crucial next step.”
Clinical studies also support the combined use of Anti-MCV and Anti-CCP tests to enhance diagnostic sensitivity without sacrificing specificity. This dual approach enables clinicians to diagnose RA at an earlier stage—when treatment is most effective in slowing disease progression and preserving joint function.
Highlighting the importance of early diagnosis, Dr. Siddhartha Sharma, Head – Clinical & Scientific Affairs, Sebia India, commented: “Timely identification of RA is essential to prevent permanent joint damage and improve long-term patient outcomes. We are proud to partner with Agilus to expand access to Anti-MCV testing across India.”
This collaboration underscores the joint mission of Agilus Diagnostics and Sebia to deliver cutting-edge, reliable diagnostics and raise the standard of care for autoimmune diseases in India.